ArticlePLoS computational biology2025
Computational modeling of ketamine-induced changes in gamma-band oscillations: The contribution of parvalbumin and somatostatin interneurons.
Article in PLoS computational biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cellular and Microcircuit Mechanisms of Anesthetic Disruption of Conscious-State Organization.Cells · 2026Review
- Aperiodic Signatures of Stress Sensitivity and Depression Recurrence in Adolescents.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2026Article
- From Monoamines to Systems Psychiatry: Rewiring Depression Science and Care (1960s-2025).Biomedicines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Ketamine, an NMDA receptor (NMDA-R) antagonist, produces psychotomimetic effects when administered in sub-anesthetic dosages. While previous research suggests that Ketamine alters the excitation/inhibition (E/I)-balance in cortical microcircuits, the precise neural mechanisms by which Ketamine produces these effects are not well understood. We analyzed resting-state MEG data from n = 12 participants who were administered Ketamine to assess changes in gamma-band (30-90 Hz) power and the slope of the aperiodic power spectrum compared to placebo. In addition, correlations of these effects with gene-expression of GABAergic interneurons and NMDA-Rs subunits were analyzed. Finally, we compared Ketamine-induced spectral changes to the effects of systematically changing NMDA-R levels on pyramidal cells, and parvalbumin-, somatostatin- and vasoactive intestinal peptide-expressing interneurons in a computational model of cortical layer-2/3 to identify crucial sites of Ketamine action. Ketamine resulted in a flatter aperiodic slope and increased gamma-band power across brain regions, with pronounced effects in prefrontal and central areas. These effects were correlated with the spatial distribution of parvalbumin and GluN2D gene expression. Computational modeling revealed that reduced NMDA-R activity in parvalbumin or somatostatin interneurons could reproduce increased gamma-band power by increasing pyramidal neuron firing rate, but did not account for changes in the aperiodic slope. The results suggest that parvalbumin and somatostatin interneurons may underlie increased gamma-band power following Ketamine administration in healthy volunteers, while changes in the aperiodic component could not be recreated. These findings have implications for current models of E/I-balance, as well as for understanding the mechanisms underlying the circuit effects of Ketamine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.